<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00393523</url>
  </required_header>
  <id_info>
    <org_study_id>V232-058</org_study_id>
    <secondary_id>2006_040</secondary_id>
    <nct_id>NCT00393523</nct_id>
  </id_info>
  <brief_title>Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)</brief_title>
  <official_title>A Study to Assess the Anamnestic Immune Response 4 to 8 Years After a Primary Vaccination Series With HBVAXPRO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and immunogenicity of a booster dose of hepatitis B vaccine in children
      who have received a 3-dose primary series of either RECOMBIVAX HB or ENGERIX-B. The primary
      vaccination series (was given 4 to 8 years prior to study entry and consisted of a licensed
      hepatitis B vaccine product (either RECOMBIVAX HB or ENGERIX-B). The booster dose given in
      this study will be either an investigational Merck product (Modified Process Hepatitis B
      Vaccine) or licensed ENGERIX-B vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of RECOMBIVAX HB in Infancy</measure>
    <time_frame>4 weeks after vaccination with either modified process hepatitis B vaccine or ENGERIX-B</time_frame>
    <description>Number of subjects who received a 3-dose primary series of RECOMBIVAX HB™ in infancy and who demonstrated antibodies to hepatitis B surface antigen ≥10 mIU/mL at 4 weeks after receiving a booster dose of modified process hepatitis B vaccine or ENGERIX-B™.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of ENGERIX-B in Infancy</measure>
    <time_frame>4 weeks after vaccination with either modified process hepatitis B vaccine or ENGERIX-B</time_frame>
    <description>Number of subjects who received a 3-dose primary series of ENGERIX-B ™ in infancy and who demonstrated antibodies to hepatitis B surface antigen ≥10 mIU/mL at 4 weeks after receiving a booster dose of modified process hepatitis B vaccine or ENGERIX-B™.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of RECOMBIVAX HB in Infancy</measure>
    <time_frame>4 weeks after vaccination with either modified process hepatitis B vaccine or ENGERIX-B</time_frame>
    <description>Geometric Mean Titer (GMT) for all subjects who completed a 3-dose primary vaccination series of RECOMBIVAX HB™ and who received a booster dose of either modified process hepatitis B vaccine or ENGERIX-B™</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of ENGERIX-B in Infancy</measure>
    <time_frame>4 weeks after vaccination with either modified process hepatitis B vaccine or ENGERIX-B</time_frame>
    <description>Geometric Mean Titer (GMT) for all subjects who completed a 3-dose primary vaccination series of ENGERIX-B™ and who received a booster dose of either modified process hepatitis B vaccine or ENGERIX-B™</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1478</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>5 µg Modified Process Hepatitis B Vaccine Booster (Group 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.
During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine (Booster Dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 µg ENGERIX-B™ Booster (Group 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.
During this study, participants received a dose of 10µg/per 0.5 ml ENGERIX-B™ (Booster Dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 µg Modified Process Hepatitis B Vaccine Booster (Group 3)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.
During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine, (Booster Dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 µg ENGERIX-B™ Booster (Group 4)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.
During this study, participants received a 10µg/0.5 ml dose of ENGERIX-B™ (Booster Dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 µg Modified Process Hepatitis B Vaccine (Group 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants did not receive a prior vaccination with a hepatitis B vaccine.
During the study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Modified Process Hepatitis B Vaccine</intervention_name>
    <description>Single dose 5 µg/0.5ml modified process hepatitis B vaccine</description>
    <arm_group_label>5 µg Modified Process Hepatitis B Vaccine Booster (Group 1)</arm_group_label>
    <arm_group_label>5 µg Modified Process Hepatitis B Vaccine Booster (Group 3)</arm_group_label>
    <arm_group_label>5 µg Modified Process Hepatitis B Vaccine (Group 5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Comparator: ENGERIX-B</intervention_name>
    <description>Single dose 10 µg/0.5ml ENGERIX-B</description>
    <arm_group_label>10 µg ENGERIX-B™ Booster (Group 2)</arm_group_label>
    <arm_group_label>10 µg ENGERIX-B™ Booster (Group 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Children 4 to 8 years of age

          -  Complete medical records documenting receiving a previous hepatitis B vaccination
             during the first year of life (for Cohort A and B only)

          -  Complete 3-dose vaccination with either a primary series of RECOMBIVAX HB or a primary
             series of ENGERIX-B (for Cohort A and B only)

        Exclusion Criteria:

          -  Birth mother known to be a carrier of hepatitis B virus (Cohort C only)

          -  History of previous hepatitis B vaccine

          -  History of vaccination with any hepatitis B vaccine (Cohort C only)

          -  Known of suspected hypersensitivity to any component of RECOMBIVAX HB or ENGERIX-B (eg
             aluminum, yeast) recent administration of hepatitis B immune globulin (HBIg), serum
             immune globulin, or any other blood-derived product

          -  Receipt of investigational drugs or vaccines within 3 months prior to study vaccine or
             planned within study period

          -  Impairment of immunologic function or recent use of immunomodulatory medications

          -  A Combination of different hepatitis B vaccines used in the primary vaccination series
             (Cohort A and B only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Diez-Domingo J, Flores SA, Martin JC, Klopfer SO, Schödel FP, Bhuyan PK. A randomized, multicenter, open-label clinical trial to assess the anamnestic immune response 4 to 8 years after a primary hepatitis B vaccination series. Pediatr Infect Dis J. 2010 Oct;29(10):972-4. doi: 10.1097/INF.0b013e3181f1b3b6.</citation>
    <PMID>20724955</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2006</study_first_posted>
  <results_first_submitted>May 27, 2009</results_first_submitted>
  <results_first_submitted_qc>September 10, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2009</results_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 77 primary study sites in Spain and 1 study site in Canada.
Date of first subject visit: 26-Sep-2006; Date of last subject visit: 23-June-2008</recruitment_details>
      <pre_assignment_details>To be eligible for enrollment in the study, participants were to have received a primary series of 3 doses of the same type of hepatitis B vaccine (either RECOMBIVAX HB or ENGERIX-B) during the first year of life.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Modified Process Hepatitis B Vaccine Booster (Group 1)</title>
          <description>Participants received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms) (Booster Dose)</description>
        </group>
        <group group_id="P2">
          <title>ENGERIX-B™ Booster (RECOMBIVAX-HB™ in Infancy) (Group 2)</title>
          <description>Participants received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study; During the study, participants received one dose of ENGERIX-B™ (10 µg (micrograms) per dose) (Booster Dose)</description>
        </group>
        <group group_id="P3">
          <title>Modified Process Hepatitis B Vaccine Booster (Group 3)</title>
          <description>Participants received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose).during the first year of life outside of the context of the study; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms) (Booster Dose)</description>
        </group>
        <group group_id="P4">
          <title>ENGERIX-B™ Booster (ENGERIX-B™ in Infancy) (Group 4)</title>
          <description>Participants received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose).during the first year of life outside of the context of the study; During the study, participants received one dose of ENGERIX-B™ (10 µg (micrograms) per dose) (Booster Dose)</description>
        </group>
        <group group_id="P5">
          <title>Modified Process Hepatitis B Vaccine (Group 5)</title>
          <description>Participants did not receive a prior vaccination with a hepatitis B vaccine; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="376"/>
                <participants group_id="P2" count="375"/>
                <participants group_id="P3" count="353"/>
                <participants group_id="P4" count="354"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="374"/>
                <participants group_id="P2" count="375"/>
                <participants group_id="P3" count="349"/>
                <participants group_id="P4" count="352"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="364"/>
                <participants group_id="P2" count="366"/>
                <participants group_id="P3" count="349"/>
                <participants group_id="P4" count="348"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Difficulties in specimen collection</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Vaccine supply issue</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modified Process Hepatitis B Vaccine Booster (Group 1)</title>
          <description>Participants received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms) (Booster Dose)</description>
        </group>
        <group group_id="B2">
          <title>ENGERIX-B™ Booster (RECOMBIVAX-HB™ in Infancy) (Group 2)</title>
          <description>Participants received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study; During the study, participants received one dose of ENGERIX-B™ (10 µg (micrograms) per dose) (Booster Dose)</description>
        </group>
        <group group_id="B3">
          <title>Modified Process Hepatitis B Vaccine Booster (Group 3)</title>
          <description>Participants received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose).during the first year of life outside of the context of the study; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms) (Booster Dose)</description>
        </group>
        <group group_id="B4">
          <title>ENGERIX-B™ Booster (ENGERIX-B™ in Infancy) (Group 4)</title>
          <description>Participants received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose).during the first year of life outside of the context of the study; During the study, participants received one dose of ENGERIX-B™ (10 µg (micrograms) per dose) (Booster Dose)</description>
        </group>
        <group group_id="B5">
          <title>Modified Process Hepatitis B Vaccine (Group 5)</title>
          <description>Participants did not receive a prior vaccination with a hepatitis B vaccine; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="376"/>
            <count group_id="B2" value="375"/>
            <count group_id="B3" value="353"/>
            <count group_id="B4" value="354"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="1478"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="0.92"/>
                    <measurement group_id="B2" value="5.7" spread="0.92"/>
                    <measurement group_id="B3" value="5.3" spread="1.05"/>
                    <measurement group_id="B4" value="5.4" spread="0.98"/>
                    <measurement group_id="B5" value="4.3" spread="0.66"/>
                    <measurement group_id="B6" value="5.5" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="161"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="711"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="193"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of RECOMBIVAX HB in Infancy</title>
        <description>Number of subjects who received a 3-dose primary series of RECOMBIVAX HB™ in infancy and who demonstrated antibodies to hepatitis B surface antigen ≥10 mIU/mL at 4 weeks after receiving a booster dose of modified process hepatitis B vaccine or ENGERIX-B™.</description>
        <time_frame>4 weeks after vaccination with either modified process hepatitis B vaccine or ENGERIX-B</time_frame>
        <population>Per-protocol population (defined as the subjects that completed the study as defined by the protocol). Subjects were excluded from the analysis population mainly because they did not receive the primary series vaccination series as defined in the protocol or the study vaccine was not maintained at proper temperature as defined in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine Booster (Group 1)</title>
            <description>Participants received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms) (Booster Dose)</description>
          </group>
          <group group_id="O2">
            <title>ENGERIX-B™ Booster (RECOMBIVAX-HB™ in Infancy) (Group 2)</title>
            <description>Participants received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study; During the study, participants received one dose of ENGERIX-B™ (10 µg (micrograms) per dose) (Booster Dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of RECOMBIVAX HB in Infancy</title>
          <description>Number of subjects who received a 3-dose primary series of RECOMBIVAX HB™ in infancy and who demonstrated antibodies to hepatitis B surface antigen ≥10 mIU/mL at 4 weeks after receiving a booster dose of modified process hepatitis B vaccine or ENGERIX-B™.</description>
          <population>Per-protocol population (defined as the subjects that completed the study as defined by the protocol). Subjects were excluded from the analysis population mainly because they did not receive the primary series vaccination series as defined in the protocol or the study vaccine was not maintained at proper temperature as defined in the protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323"/>
                    <measurement group_id="O2" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The primary purpose of this study was to show that subjects who received a primary series of RECOMBIVAX HB™ in the first year of life were adequately protected by RECOMBIVAX HB™ by measuring the immune response to a single booster dose of either a modified process vaccine or ENGERIX-B™.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adequate SPR required the lower bound of the 95.2% CI for the SPR for subjects in both Group 1 and Group 2 to be &gt; 90% (P-Value &lt; .024).
Since only one group met the criteria, that group was retested at α=.012.</p_value_desc>
            <method>Hochberg's step up</method>
            <method_desc>The primary hypothesis was evaluated using Hochberg’s step up approach to control multiplicity.</method_desc>
            <param_type>Seroprotection rate (SPR)</param_type>
            <param_value>95.0</param_value>
            <ci_percent>95.2</ci_percent>
            <ci_lower_limit>92.1</ci_lower_limit>
            <ci_upper_limit>97.1</ci_upper_limit>
            <estimate_desc>Seroprotection rate (SPR)- defined as the percentage of subjects who demonstrate antibodies to hepatitis B surface antigen ≥10 mIU/mL</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The primary purpose of this study was to show that subjects who received a primary series of RECOMBIVAX HB™ in the first year of life were adequately protected by RECOMBIVAX HB™ by measuring the immune response to a single booster dose of either a modified process vaccine or ENGERIX-B™.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adequate SPR required the lower bound of the 95.2% CI for the SPR for subjects in both Group 1 and Group 2 to be &gt; 90% (P-Value &lt; .024). Since only one group met the criteria, that group was retested at α=.012.</p_value_desc>
            <method>Hochberg's step up</method>
            <method_desc>The primary hypothesis was evaluated using Hochberg’s step up approach to control multiplicity.</method_desc>
            <param_type>Seroprotection rate (SPR)</param_type>
            <param_value>95.0</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_lower_limit>91.6</ci_lower_limit>
            <ci_upper_limit>97.3</ci_upper_limit>
            <estimate_desc>Seroprotection rate (SPR)- defined as the percentage of subjects who demonstrate antibodies to hepatitis B surface antigen ≥10 mIU/mL</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary purpose of this study was to show that subjects who received a primary series of RECOMBIVAX HB™ in the first year of life were adequately protected by RECOMBIVAX HB™ by measuring the immune response to a single booster dose of either a modified process vaccine or ENGERIX-B™.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <p_value_desc>Adequate SPR required the lower bound of the 95.2% CI for the SPR for subjects in both Group 1 and Group 2 to be &gt; 90% (P-Value &lt; .024).
Since only one group met the criteria, that group was retested at α=.012.</p_value_desc>
            <method>Hochberg's step up</method>
            <method_desc>The primary hypothesis was evaluated using Hochberg’s step up approach to control multiplicity.</method_desc>
            <param_type>Seroprotection rate (SPR)</param_type>
            <param_value>91.6</param_value>
            <ci_percent>95.2</ci_percent>
            <ci_lower_limit>88.0</ci_lower_limit>
            <ci_upper_limit>94.4</ci_upper_limit>
            <estimate_desc>Seroprotection rate (SPR)- defined as the percentage of subjects who demonstrate antibodies to hepatitis B surface antigen ≥10 mIU/mL</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of ENGERIX-B in Infancy</title>
        <description>Number of subjects who received a 3-dose primary series of ENGERIX-B ™ in infancy and who demonstrated antibodies to hepatitis B surface antigen ≥10 mIU/mL at 4 weeks after receiving a booster dose of modified process hepatitis B vaccine or ENGERIX-B™.</description>
        <time_frame>4 weeks after vaccination with either modified process hepatitis B vaccine or ENGERIX-B</time_frame>
        <population>Per-protocol population (defined as the subjects that completed the study as defined by the protocol). Subjects were excluded from the analysis population mainly because they did not receive the primary series vaccination series as defined in the protocol or the study vaccine was not maintained at proper temperature as defined in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine Booster (Group 3)</title>
            <description>Participants received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose).during the first year of life outside of the context of the study; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms) (Booster Dose)</description>
          </group>
          <group group_id="O2">
            <title>ENGERIX-B™ Booster (ENGERIX-B™ in Infancy) (Group 4)</title>
            <description>Participants received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose).during the first year of life outside of the context of the study; During the study, participants received one dose of ENGERIX-B™ (10 µg (micrograms) per dose) (Booster Dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of ENGERIX-B in Infancy</title>
          <description>Number of subjects who received a 3-dose primary series of ENGERIX-B ™ in infancy and who demonstrated antibodies to hepatitis B surface antigen ≥10 mIU/mL at 4 weeks after receiving a booster dose of modified process hepatitis B vaccine or ENGERIX-B™.</description>
          <population>Per-protocol population (defined as the subjects that completed the study as defined by the protocol). Subjects were excluded from the analysis population mainly because they did not receive the primary series vaccination series as defined in the protocol or the study vaccine was not maintained at proper temperature as defined in the protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329"/>
                    <measurement group_id="O2" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The purpose of the secondary analysis is to demonstrate that there is an adequate SPR in subjects who received a primary vaccination series of ENGERIX-B™ and a booster dose of modified process hepatitis B vaccine. An adequate response requires the lower bound of the two-sided 95% confidence interval for the SPR to exceed 90%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Seroprotection Rate (SPR)</param_type>
            <param_value>97.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>95.0</ci_lower_limit>
            <ci_upper_limit>98.8</ci_upper_limit>
            <estimate_desc>Exact binomial confidence interval
Seroprotection Rate (SPR)- defined as the percentage of subjects who demonstrate antibodies to hepatitis B surface antigen ≥10 mIU/mL</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of RECOMBIVAX HB in Infancy</title>
        <description>Geometric Mean Titer (GMT) for all subjects who completed a 3-dose primary vaccination series of RECOMBIVAX HB™ and who received a booster dose of either modified process hepatitis B vaccine or ENGERIX-B™</description>
        <time_frame>4 weeks after vaccination with either modified process hepatitis B vaccine or ENGERIX-B</time_frame>
        <population>Per-protocol population (defined as the subjects that completed the study as defined by the protocol). Subjects were excluded from the analysis population mainly because they did not receive the primary series vaccination series as defined in the protocol or the study vaccine was not maintained at proper temperature as defined in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine Booster (Group 1)</title>
            <description>Participants received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms) (Booster Dose)</description>
          </group>
          <group group_id="O2">
            <title>ENGERIX-B™ Booster (RECOMBIVAX-HB™ in Infancy) (Group 2)</title>
            <description>Participants received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study; During the study, participants received one dose of ENGERIX-B™ (10 µg (micrograms) per dose) (Booster Dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of RECOMBIVAX HB in Infancy</title>
          <description>Geometric Mean Titer (GMT) for all subjects who completed a 3-dose primary vaccination series of RECOMBIVAX HB™ and who received a booster dose of either modified process hepatitis B vaccine or ENGERIX-B™</description>
          <population>Per-protocol population (defined as the subjects that completed the study as defined by the protocol). Subjects were excluded from the analysis population mainly because they did not receive the primary series vaccination series as defined in the protocol or the study vaccine was not maintained at proper temperature as defined in the protocol.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476.9" lower_limit="380.7" upper_limit="597.3"/>
                    <measurement group_id="O2" value="561.2" lower_limit="435.6" upper_limit="723.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of ENGERIX-B in Infancy</title>
        <description>Geometric Mean Titer (GMT) for all subjects who completed a 3-dose primary vaccination series of ENGERIX-B™ and who received a booster dose of either modified process hepatitis B vaccine or ENGERIX-B™</description>
        <time_frame>4 weeks after vaccination with either modified process hepatitis B vaccine or ENGERIX-B</time_frame>
        <population>Per-protocol population (defined as the subjects that completed the study as defined by the protocol). Subjects were excluded from the analysis population mainly because they did not receive the primary series vaccination series as defined in the protocol or the study vaccine was not maintained at proper temperature as defined in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine Booster (Group 3)</title>
            <description>Participants received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose).during the first year of life outside of the context of the study; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms) (Booster Dose)</description>
          </group>
          <group group_id="O2">
            <title>ENGERIX-B™ Booster (ENGERIX-B™ in Infancy) (Group 4)</title>
            <description>Participants received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose).during the first year of life outside of the context of the study; During the study, participants received one dose of ENGERIX-B™ (10 µg (micrograms) per dose) (Booster Dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of ENGERIX-B in Infancy</title>
          <description>Geometric Mean Titer (GMT) for all subjects who completed a 3-dose primary vaccination series of ENGERIX-B™ and who received a booster dose of either modified process hepatitis B vaccine or ENGERIX-B™</description>
          <population>Per-protocol population (defined as the subjects that completed the study as defined by the protocol). Subjects were excluded from the analysis population mainly because they did not receive the primary series vaccination series as defined in the protocol or the study vaccine was not maintained at proper temperature as defined in the protocol.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1424.0" lower_limit="1131.1" upper_limit="1792.8"/>
                    <measurement group_id="O2" value="1216.1" lower_limit="923.6" upper_limit="1601.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Of the 1478 total participants in this study, 8 did not receive study vaccine, 17 received the incorrect study vaccine (different than what they were supposed to receive as part of the study), and 11 did not have safety follow-up information available. Thus, the total number of participants included in the safety analyses is 1442.</desc>
      <group_list>
        <group group_id="E1">
          <title>Modified Process Hepatitis B Vaccine Booster (Group 1)</title>
          <description>Participants received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms) (Booster Dose)</description>
        </group>
        <group group_id="E2">
          <title>ENGERIX-B™ Booster (RECOMBIVAX-HB™ in Infancy) (Group 2)</title>
          <description>Participants received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study; During the study, participants received one dose of ENGERIX-B™ (10 µg (micrograms) per dose) (Booster Dose)</description>
        </group>
        <group group_id="E3">
          <title>Modified Process Hepatitis B Vaccine Booster (Group 3)</title>
          <description>Participants received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose).during the first year of life outside of the context of the study; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms) (Booster Dose)</description>
        </group>
        <group group_id="E4">
          <title>ENGERIX-B™ Booster (ENGERIX-B™ in Infancy) (Group 4)</title>
          <description>Participants received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose).during the first year of life outside of the context of the study; During the study, participants received one dose of ENGERIX-B™ (10 µg (micrograms) per dose) (Booster Dose)</description>
        </group>
        <group group_id="E5">
          <title>Modified Process Hepatitis B Vaccine (Group 5)</title>
          <description>Participants did not receive a prior vaccination with a hepatitis B vaccine; During the study, participants received one dose of Modified Process Hepatitis B Vaccine, 5 µg (micrograms)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="198" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="194" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Motion Sickness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eye Discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bruising, Injection site for hepatitis B vaccine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Erythema, Injection site for hepatitis B vaccine</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hematoma, Injection site for hepatitis B vaccine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypersensitivity, Injection site for hepatitis B vaccine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Induration, Injection site for hepatitis B vaccine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Edema, Injection site for hepatitis B vaccine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain, Injection site for hepatitis B vaccine</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="95" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Paraesthesia, Injection site for hepatitis B vaccine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pruritus, Injection site for hepatitis B vaccine</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Scar, Injection site for hepatitis B vaccine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Swelling, Injection site for hepatitis B vaccine</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vesicles, Injection site for hepatitis B vaccine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Warmth, Injection site for hepatitis B vaccine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chillblains</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Epiphysiolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rhinitis seasonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

